Sterling Pharma Solutions
Christopher Bayley is a seasoned professional in the field of biochemistry and analytical sciences, currently serving as a Senior QC Analytical Scientist (Bioassay) at Sterling Pharma Solutions since November 2021, specializing in cell-based bioassay development and validation. Prior experience includes a role as a Senior Production Scientist at BioServUK Ltd, where analytical and downstream processing services were provided to an international clientele, along with significant experience in production systems. At Sartorius Stedim BioOutsource, Christopher held multiple positions, advancing from Scientist I to Scientist III, focusing on analytical SPR services and project management for biosimilar data submissions. Previous research as a Postdoctoral Research Associate at The University of Manchester involved assay development in mucin biology and protein-protein interactions. Christopher obtained a PhD in the Structure and Function of Platelet-derived Growth Factor Receptor Alpha from The University of Manchester after earning a BSc in Biochemistry from The University of Sheffield.
This person is not in the org chart
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities